Portal de Periódicos da CAPES

Systematic identification of arsenic-binding proteins reveals that hexokinase-2 is inhibited by arsenic

2015; National Academy of Sciences; Volume: 112; Issue: 49 Linguagem: Inglês

10.1073/pnas.1521316112

1091-6490

Hai‐nan Zhang, Lina Yang, Jian-ya Ling, Daniel M. Czajkowsky, Jing‐Fang Wang, Xiao-Wei Zhang, Yi-ming Zhou, Feng Ge, Ming-kun Yang, Qian Xiong, Shu-Juan Guo, Huang-Ying Le, Songfang Wu, Wei Yan, Bingya Liu, Heng Zhu, Chen Zhu, Sheng‐ce Tao,

Acute Myeloid Leukemia Research

Arsenic is highly effective for treating acute promyelocytic leukemia (APL) and has shown significant promise against many other tumors. However, although its mechanistic effects in APL are established, its broader anticancer mode of action is not understood. In this study, using a human proteome microarray, we identified 360 proteins that specifically bind arsenic. Among the most highly enriched proteins in this set are those in the glycolysis pathway, including the rate-limiting enzyme in glycolysis, hexokinase-1. Detailed biochemical and metabolomics analyses of the highly homologous hexokinase-2 (HK2), which is overexpressed in many cancers, revealed significant inhibition by arsenic. Furthermore, overexpression of HK2 rescued cells from arsenic-induced apoptosis. Our results thus strongly implicate glycolysis, and HK2 in particular, as a key target of arsenic. Moreover, the arsenic-binding proteins identified in this work are expected to serve as a valuable resource for the development of synergistic antitumor therapeutic strategies.